BridgeMD
Prevention study for Multiple Myeloma
Official title Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
ClinicalTrials.gov ID: NCT07413809
What this study is testing
What is Fosaprepitant?
Fosaprepitant is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for multiple myeloma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT). A total of 92 patients with multiple myeloma who were indicated for autologous HSCT were enrolled.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Patients with multiple myeloma who are indicated for autologous hematopoietic stem cell transplantation;
- Preconditioning regimen consists of melphalan at a dose of 200 mg/m²;
- ECOG performance status score of 0 to 2;
- Age \>18 years and \<65 years;
- Expected survival time \>3 months;
You likely can't join if
- Presence of nausea or vomiting within 48 hours prior to enrollment, with prior use of antiemetic medications;
- Current use or use within the past month of CYP3A4 inducers, inhibitors, or substrate drugs;
- History of hypersensitivity to fosaprepitant or olanzapine;
- Serum creatinine clearance \<60 mL/min;
- Inability to receive treatment and follow-up at the designated study site, or inability to comprehend, comply with the study protocol, or provide...
See the full eligibility criteria
- Patients with multiple myeloma who are indicated for autologous hematopoietic stem cell transplantation;
- Preconditioning regimen consists of melphalan at a dose of 200 mg/m²;
- ECOG performance status score of 0 to 2;
- Age \>18 years and \<65 years;
- Expected survival time \>3 months;
- Absence of intracranial hypertension, gastrointestinal obstruction, or other causes of refractory vomiting;
- Ability to understand and provide written informed consent.
- Presence of nausea or vomiting within 48 hours prior to enrollment, with prior use of antiemetic medications;
- Current use or use within the past month of CYP3A4 inducers, inhibitors, or substrate drugs;
- History of hypersensitivity to fosaprepitant or olanzapine;
- Serum creatinine clearance \<60 mL/min;
- Inability to receive treatment and follow-up at the designated study site, or inability to comprehend, comply with the study protocol, or provide informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Ningbo, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ningbo, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.